Lady Hardinge Medical College, India
Posters & Accepted Abstracts: J Blood Disord Transfus
The aim of the trial was to study the efficacy and safety of intravenous ferric carboxymaltose (FCM) in gynaecological patients with iron deficiency anemia (IDA) in terms of time of onset of response, improvement in haematological parameters, qualitative improvement in symptoms and adverse effects. A prospective observational study was conducted in a tertiary hospital for duration of one year. 30 gynaecological patients having IDA with Hb 6-8 g/dl and serum ferritin <15μg/L were given intravenous 1000 mg FCM over two weeks (500 mg X 2 infusions). Changes in haematological variables, improvement in clinical parameters and adverse effects were studied over a period of four weeks. At the end of study, Hb increment of �?�3 g% was seen in more than half of patients. Mean Hb increased to 10.14 g/dl from baseline value of 6.97 g/dl at the end of the study with only two infusions of FCM. MCV normalized in 43.33% of women on day 14 and in 100% of women on day 28. Mean serum ferritin increased from baseline value of 7.88 μg/L to 147.70 μg/L on day 28 reflecting replenishment of iron stores. Significant improvement in clinical parameters like fatigue, dyspnoea, palpitations was observed. Minor side effects like headache, dizziness and thrombophlebitis were observed in 13.33%, 10.00% and 6.67% women respectively. We concluded that intravenous FCM is effective, safe and convenient for treatment of IDA in gynaecological patients.